Experimental drug combo targets tough bone cancer

NCT ID NCT04833582

Completed Disease control Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called azenosertib (ZN-c3) combined with the chemotherapy gemcitabine in 31 people aged 12 and older with osteosarcoma that had relapsed or stopped responding to treatment. The goal was to see if the combination is safe and whether it can slow or stop tumor growth. The study is now complete, and results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Azenosertib (ZN-c3) combined with gemcitabine
What this could lead to: If it works, this could offer a new treatment option for people with osteosarcoma that has come back or not responded to standard therapy.
What could go wrong: This is an early phase 1/2 trial with only 31 participants, so results are preliminary. The combination may cause significant side effects and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOSARCOMA

Contacts and locations

Locations

Site 0103

Houston, Texas, 77030, United States
Site 0105

New York, New York, 10065, United States
Site 0106

Los Angeles, California, 90095, United States
Site 0107

Cincinnati, Ohio, 45229, United States
Site 0122

Seattle, Washington, 98195, United States
Site 0123

Portland, Oregon, 97239, United States
Site 0124

Oakland, California, 94609, United States
Site 0188

Richmond, Virginia, 23298, United States
Site 0193

Memphis, Tennessee, 38105, United States
Site 0195

Santa Monica, California, 90403, United States
Site 0197

Nashville, Tennessee, 37332, United States
Site 3601

Lyon, 69008, France
Site 3602

Marseille, 13385, France
Site 3604

Bordeaux, 33000, France
Site 3605

Toulouse, 31100, France
Site 3606

Paris, 75248, France
University of Florida College of Medicine

Gainesville, Florida, 32610, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.